NNVC is testing at the least 4 facilities. The testing is being done at the exdpense of others. Two of those facilities are using grant money. One of those facilities, SRI, is obviously using NIH funds. The other is most probably using part of its $11 million NIH antiviral grant money.
How can you possibly say there is a lack of progress for a company that has 4 drugs in the pipeline and will be completing animal testing in early 2010?
The thing that really bothers me though is your posts claim you are long on this company, yet the posts make these spurious claims that undermine the value of the company. The current market cap is over $100 million with drugs still in pre-clinical testing. AVI has drugs in clinical trials, yet they are valued only at adouble? I think AVI has the problem.
Oh, and by the way, AVI has been working on their platforms for more than 25 years yet they have never brought a drug to market. Interesting that.